HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Retin-A .04%

This article was originally published in The Rose Sheet

Executive Summary

Ortho Neutrogena's Retin-A Micro (tretinoin gel) .04% microspheres approved by FDA May 10. The .04% dosage joins four year-old .1% formulation of the topical gel for acne vulgaris. Labeling for new version states, "There is no evidence that Retin-A Micro .1% is more efficacious than Retin-A Micro .04% or that Retin-A Micro .04% is safer than Retin-A Micro .1%." Ortho Neutrogena was formed in July 2001 when Ortho Dermatological and the professional division of Neutrogena were combined...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS010325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel